24.4 C
New York
Tuesday, August 16, 2022

Minerva Neurosciences, Inc. (NERV) Is Rising in Premarket Today – What’s Driving It Higher?

Minerva Neurosciences, Inc. (NERV) has seen a push of 6.52% in the premarket today. However, the last trading session closed at $1.84 with an incline of 9.52%.

Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

NERV announced the appointment of Dr. Ramana Kuchibhatla on 8th September 2-2021. Dr. Ramana Kuchibhatla’s is appointed as Senior Vice President and Head of Research and Development.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Firstly, Dr. Kuchibhatla has over 35 years of expertise in the life sciences and biotechnology sectors. This includes drug development, regulatory, biostatistical, and operations leadership. He comes to Minerva from PRA Health Sciences Inc, where he was the Executive Director of Global Drug Development. Secondly, Dr. Kuchibhatla previously worked at Melior Pharmaceuticals Inc. as the Senior Vice President of Clinical Development and Biostatistics.

Thirdly, he previously created QED Pharmaceutical Services, a contract research business specialized in clinical and data services, and worked at Targacept Inc as Senior Director of Clinical R&D. Last but not least, he held several positions of increasing significance within GlaxoSmithKline Inc’s neurology and psychiatry department, where he was engaged in the submission of NDAs for Zyban and Lamictal.

NERV announces Second Quarter 2021 Financial Results

NERV published second quarter 2021 financial results on 2 August 2021. In the second quarter of 2021, the company lost $10.6 million, or $0.25 per basic and diluted share. For the six months ended June 30, 2021, net loss was $19.4 million, or $0.45 basic and diluted net loss per share.

The Company’s decision to opt-out of its collaborative development agreement with Janssen Pharmaceutica resulted in reductions in net income for both the three and six months ended June 30, 2021. The Company recognized $41.2 million in collaboration revenue immediately as a result of opting out of the agreement.

Results of the Phase 3 Trial of Roluperidone

NERV reported the findings of roluperidone’s phase 3 study on 11 May 2021. The study declared for the treatment of negative symptoms (NS) of schizophrenia’s 40-week open-label extension (OLE). Moreover, 333 individuals took part in the OLE study over the course of 40 weeks, with 166 receiving the 32 mg dosage and 167 receiving the 64 mg dose. The 32 mg arm had a 6.8 point improvement in negative symptoms, whereas the 64 mg arm saw a 7.5 point improvement. Lastly, the PSP total score increased by an average of 12.3 points in the 32 mg arm and 14.5 points in the 64 mg arm, indicating better function.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2887

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

DOWNLOAD FREE EBOOK

BEST INFLATION STOCKS 2022

We put together a list of the best stocks that

we think can explode over the next 12 months.

2888

SPECIAL GIFT

2889
2890
2891

  What you will Get ?

   Best Inflation

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

100% free. stop anytime no spam

GET YOUR FREE COPY NOW

DOWNLOAD FREE EBOOK

BEST GROWTH STOCKS 2022

We put together a list of the best stocks that we

think can explode over the next 12 months.

2899

SPECIAL GIFT

2900
2901
2902

  What you will Get ?

   Best Growth

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

2903

100% free. stop anytime no spam

GET YOUR FREE COPY NOW

2915

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

2839

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam